Development of cancer therapy-related cardiac dysfunction in anthracycline-treated breast cancer patients: a retrospective study
Junko Kuroda, Masayoshi Oikawa, Emi Tokuda, Kazunoshin Tachibana, Eisaku Sasaki, Tohru Ohtake, Yasuchika Takeishi, Shigehira Saji · 2024
Read Development of cancer therapy-related cardiac dysfunction in anthracycline-treated breast cancer patients: a retrospective study by Junko Kuroda, Masayoshi Oikawa, Emi Tokuda, Kazunoshin Tachibana, Eisaku Sasaki, Tohru Ohtake, Yasuchika Takeishi, Shigehira Saji (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11625689.txt.
Description
Junko Kuroda and seven colleagues look for warning signs that breast cancer chemotherapy will weaken the heart, in a 2024 retrospective study. Anthracycline drugs can injure heart muscle, and spotting vulnerable patients early could change their care.
One hundred seventy-seven patients on anthracyclines saw cardiologists regularly, with heart scans and blood markers tracked for a year. Eight patients, about four and a half percent, developed treatment-related heart dysfunction. They stood out beforehand by later cancer stage and a high inflammation ratio in the blood. The drug type mattered too, with doxorubicin riskier than its cousin. The authors urge close heart monitoring for patients carrying any of these flags.
Catalog record
| CREATOR | Junko Kuroda, Masayoshi Oikawa, Emi Tokuda, Kazunoshin Tachibana, Eisaku Sasaki, Tohru Ohtake, Yasuchika Takeishi, Shigehira Saji |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |